logo

KOPRAN vs MEDICAMEQ: Stock Comparison

KOPRAN vs MEDICAMEQUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

KOPRAN is the larger company by market capitalisation. KOPRAN shows a higher ROE, a higher dividend yield and lower leverage, while MEDICAMEQ shows a lower P/E, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KOPRAN leads 5; MEDICAMEQ leads 6 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KOPRANMEDICAMEQ

Valuation lens

What price are you paying?

Market CapContext only
₹1,256 Cr
₹362 Cr
P/E RatioMEDICAMEQ has the lower reading
50.29x
36.16x ✓
P/B RatioMEDICAMEQ has the lower reading
2.37x
1.42x ✓
EPSMEDICAMEQ has the higher reading
₹1.39
₹1.56 ✓
Book ValueContext only
₹109.82
₹203.17
Dividend YieldKOPRAN has the higher reading
1.12% ✓
0.37%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
KOPRAN is the larger company
₹1,256 Cr vs ₹362 Cr
P/E Ratio
MEDICAMEQ has a lower P/E
36.16x vs 50.29x
P/B Ratio
MEDICAMEQ has a lower P/B
1.42x vs 2.37x
EPS
MEDICAMEQ has higher earnings per share
₹1.56 vs ₹1.39
Dividend Yield
KOPRAN has a higher dividend yield
1.12% vs 0.37%
Revenue Growth (TTM YoY)
MEDICAMEQ has faster revenue growth
80.2% vs -3.66%
EPS Growth (TTM YoY)
MEDICAMEQ has faster EPS growth
44.7% vs -71.88%
ROE
KOPRAN has a higher ROE
6.79% vs 3.36%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANMEDICAMEQ
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANMEDICAMEQ
Live Price₹261.65₹346.3
Day Change-0.91%0.23%
Volume6.23 L1.29 L
52-Week High₹295.83₹447.65
52-Week Low₹107₹212.4
Distance from 52W High-11.55%-22.64%

Valuation

MetricKOPRANMEDICAMEQ
Market Cap₹1,256 Cr₹362 Cr
P/E Ratio50.29x36.16x
P/B Ratio2.37x1.42x
EPS₹1.39₹1.56
Book Value₹109.82₹203.17
Dividend Yield1.12%0.37%

Growth

MetricKOPRANMEDICAMEQ
Revenue Growth (TTM YoY)-3.66%80.2%
EPS Growth (TTM YoY)-71.88%44.7%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKOPRANMEDICAMEQ
ROE6.79%3.36%
ROCE6.79%4.09%
Net Margin3.78%5.21%
Operating Margin14.59%8.01%
Debt to Equity0.1x0.13x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKOPRANMEDICAMEQ
Promoter Holding41.82%▼ 2.6 pp40.46%
FII Holding0.91%▲ 0.4 pp0.07%▼ 0.03 pp
DII Holding0%0.4%▲ 0.4 pp
Public Holding57.27%▲ 2.21 pp59.02%▼ 0.37 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KOPRAN and MEDICAMEQ.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.